Complement in monoclonal antibody therapy of cancer - Wikidata - awgldk - TriplyDB

Complement in monoclonal antibody therapy of cancer

Complement in monoclonal antibody therapy of cancer

http://www.wikidata.org/entity/Q26860800

about

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice Building better monoclonal antibody-based therapeutics.Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential Monoclonal antibodies: technologies for early discovery and engineering.New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells.Trichothecenes: immunomodulatory effects, mechanisms, and anti-cancer potential.The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells.CAR-T cells: the long and winding road to solid tumors.[The complement system: a double edge sword in tumor progression].

P2860

Q33707941-CC5012B0-1A6A-4C10-A352-CA35EE205264 Q35817552-4B5A5AE2-F155-4979-88D0-A9AC51696B5B Q37193096-49919005-8D80-4219-AE9F-9668122C4BE6 Q38633596-AA277A4F-7A8F-4F80-AF33-80E2770CB61E Q38648979-DFF74598-6F09-4802-8366-9017DF128A84 Q41842699-F796CC35-E7E0-4F2D-9316-D7BA0B247964 Q47448492-737E5786-23DA-4D2D-8BAE-A54D863F56CC Q47870060-7DCE2242-4329-4DA2-A9F2-0C4761810ACE Q49959264-91B5F76B-9638-4B2D-95ED-7179C08FBA4F Q50243745-5E81BA64-9AA5-43AB-B234-42F57D1F727A

P2860

Complement in monoclonal antibody therapy of cancer

http://www.wikidata.org/entity/Q26860800

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Complement in monoclonal antibody therapy of cancer

@ast

Complement in monoclonal antibody therapy of cancer

@en

Complement in monoclonal antibody therapy of cancer

@nl

type

label

Complement in monoclonal antibody therapy of cancer

@ast

Complement in monoclonal antibody therapy of cancer

@en

Complement in monoclonal antibody therapy of cancer

@nl

prefLabel

Complement in monoclonal antibody therapy of cancer

@ast

Complement in monoclonal antibody therapy of cancer

@en

Complement in monoclonal antibody therapy of cancer

@nl

P1433

Q26860800-64FDD033-9D51-4C81-BCFC-13585D3BFE2E

P1476

Q26860800-C4D8FC18-98FF-4C24-A30B-6D02424A0B1B

P2093

Q26860800-B9B7A8DD-A159-4351-946E-180E4F428C3C

P2860

Q26860800-03A993A4-00C2-41AE-9EB0-B7580503BC83

Q26860800-077C4BD3-E4EA-4AA6-A210-10494193B6DA

Q26860800-08412532-FEDB-4121-BC64-6791CBA6C63C

Q26860800-084F917F-7A50-4714-A61E-339EED7055EF

Q26860800-0B15B805-7C20-4B87-B01C-7718EF0B2CDB

Q26860800-0BEB845E-C5CE-4D4B-848F-738337F25425

Q26860800-0D087A23-A39B-4526-A3F9-AE7E84D2F141

Q26860800-105FE900-0A8A-4B5E-9EFB-73125E404E30

Q26860800-133C78AE-8FDF-47E4-B605-D09FED1A5A20

Q26860800-19FEA5AE-1DB5-4FE1-BDE4-7AB3001AC6B3

P2888

Q26860800-A3634D1F-D226-419F-9752-F7A7376938D2

P304

Q26860800-EC41042A-3DBB-4155-8993-1EBAF26B0ED7

P31

Q26860800-638D32AB-0A58-4A08-B6AA-B1BBB1480CC6

P3181

Q26860800-9DB3E4FA-D61B-40B0-8EA3-FAA1E93DD936

P356

Q26860800-4F17DCEA-1E6B-4841-BA77-8275FD1F48E3

P407

Q26860800-7BE24FE9-4572-4432-A69C-C0500EB96C27

P433

Q26860800-8D9C6B55-A906-414C-88B4-1A9CBD2E34A7

P478

Q26860800-1FAFF54C-5C7B-41C9-9E14-CBE8E5270684

P50

Q26860800-19AB46D4-E122-4EF7-938D-9DEC44B894C6

Q26860800-611AE0FB-F7ED-4E4A-A10C-BECB56972C4E

P577

Q26860800-E45C5736-BC3D-4E33-BBDB-E497305E0847

P6179

Q26860800-17525670-0734-4405-9139-57E15DB74B80

P698

Q26860800-1C981FB6-E500-46A2-95F4-9F05EBE8C8EB

P921

Q26860800-6B1B1171-E920-46D7-AA8E-61A2F18D2AEE

P932

Q26860800-98AC1C23-B925-4E7F-96B8-9926E68D3F9F

P3181

P356

S12026-014-8542-Z

P1433

Immunologic Research

P1476

Complement in monoclonal antibody therapy of cancer

@en

P2093

Laura M Rogers

http://www.w3.org/2001/XMLSchema#string

P2860

The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)

Complement factor H related proteins (CFHRs)

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1

Fcgamma receptors: old friends and new family members

Complement: a key system for immune surveillance and homeostasis

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.

P2888

s12026-014-8542-z

P304

203-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3965996

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S12026-014-8542-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

George J Weiner

Suresh Veeramani

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003175942

http://www.w3.org/2001/XMLSchema#string

P698

24906530

http://www.w3.org/2001/XMLSchema#string

P921

P932

4381956

http://www.w3.org/2001/XMLSchema#string